Imdelltra plus Imfinzi cuts death risk by 58% in first‑line extensive‑stage small cell lung cancer
Amgen and AstraZeneca reported that the Phase 3 DeLLphi‑305 trial showed the combination of Amgen’s tarlatamab (Imdelltra) with AstraZeneca’s durvalumab (Imfinzi) reduced the hazard of death by 58% versus Imfinzi alone in extensive‑stage small cell lung cancer. Median overall survival was 21.1 months with the combo compared with 12.7 months on Imfinzi alone, and the one‑year survival rate was 79% versus 53%. The study enrolled 563 patients and also demonstrated a 66% reduction in disease progression risk, with median progression‑free survival of 7.4 months versus 1.9 months.
Why it matters
Amgen said the results boost the commercial outlook for Imdelltra, noting Q2 2026 sales of $288 million, up 115% year‑over‑year. The strong efficacy may expand the drug’s market and drive future regulatory submissions.
Key facts
- 1The trial enrolled 563 patients. astrazeneca.com
- 2Hazard ratio for death was 0.42 (95 % CI 0.32‑0.54). astrazeneca.com
- 3Median overall survival was 21.1 months with the combination versus 12.7 months with Imfinzi alone. astrazeneca.com
- 4One‑year overall‑survival rate was 79 % with the combo and 53 % with Imfinzi alone. astrazeneca.com
- 5Hazard ratio for disease progression or death was 0.34 (95 % CI 0.28‑0.42). astrazeneca.com
- 6Median progression‑free survival was 7.4 months versus 1.9 months. astrazeneca.com
Summary written by AlphAI AI Desk from 20 of 34 sources. Not investment advice. Figures are as stated by the linked sources.